Question 1

What is Omalizumab?

Accepted Answer

Omalizumab is a Other.

Question 2

How often does Omalizumab appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 9 articles.

Question 3

When was Omalizumab first tracked by Ergen?

Accepted Answer

First tracked on Jun 13, 2026.

Question 4

When was Omalizumab last mentioned in news?

Accepted Answer

Last active on Jun 13, 2026.

Question 5

What is Omalizumab's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Omalizumab in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Omalizumab?

Accepted Answer

Alpha-Gal Syndrome Cases Rise, New Treatments (Jun 13, 2026, 9 articles).

Question 8

How did the "Alpha-Gal Syndrome Cases Rise, New Treatments" event impact Omalizumab?

Accepted Answer

Omalizumab is an injectable drug approved by the United States — Food and Drug Administration in 2024 to reduce severe allergic reactions from alpha-gal syndrome, offering a new treatment option for patients.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.